Harvard Bioscience (HBIO) Equity Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Equity Average data on file, last reported at $11.9 million in Q1 2026.

• Equity Average for Q1 2026 came in at $11.9 million, down 69.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 million (down 69.58% YoY), and the FY2025 annual result was $38.5 million, down 43.5% from the prior year.
• Equity Average retreated to $11.9 million in Q1 2026 per HBIO's latest filing, from $13.9 million in the prior quarter.
• Over five years, Equity Average peaked at $79.9 million in Q1 2022 and troughed at $11.9 million in Q1 2026.
• A 5-year average of $56.8 million and a median of $70.9 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average grew 3.89% in 2022, then sank 78.39% in 2025.
• A 5-year view of Equity Average shows it stood at $72.1 million in 2022, then rose by 2.19% to $73.7 million in 2023, then decreased by 12.69% to $64.3 million in 2024, then slumped by 78.39% to $13.9 million in 2025, then decreased by 14.47% to $11.9 million in 2026.
• Business Quant data shows HBIO's Equity Average at $11.9 million in Q1 2026, $13.9 million in Q4 2025, and $14.9 million in Q3 2025.